Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02292043

Enrollment

Registered

2014-11-17

Start date

2013-05-31

Completion date

2015-01-31

Last updated

2014-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure

Brief summary

The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction.

Detailed description

The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction. The specific index is 6 miniutes walk distance, echocardiography, NYHA, NTproBNP level, peripherial WBC, RBC, PLT, Cre, UA, K+, Na+ upon entrance to hospital and 4 weeks after HTEA treatment, and 3 months after discharge. The morbidity and re-hospitalization would also calculated 3 months after discharge.

Interventions

DRUGHTEA

HTEA

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* 90 chronic cardiac failure patients in our hospital were selected and divided into two groups.

Exclusion criteria

* Vavular diseases

Design outcomes

Primary

Measure	Time frame
Morbidity	1 months to 3 months after discharge

Secondary

Measure	Time frame
The decreased degree of NT-proBNP higher than 30%	3 months after discharge

Countries

China

Contacts

Primary Contactwei liu, Ph.D.

86-18904502999

Backup Contactxiaohui ren

86-451-85552320

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026